Proteomics discovery of pulmonary hypertension biomarkers: Insulin‐like growth factor binding proteins are associated with disease severity. (20th April 2022)

• Record Type: Journal Article
• Authors: Nies, Melanie K.; Yang, Jun; Griffiths, Megan; Damico, Rachel; Zhu, Jie; Vaydia, Dhananjay; Fu, Zongming; Brandal, Stephanie; Austin, Eric D.; Ivy, Dunbar D.; Hassoun, Paul M.; Van Eyk, Jennifer E.; Everett, Allen D.
• Is Part Of: Pulmonary circulation. Volume 12:Number 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-20
• Subjects: biomarker -- IGF binding protein -- proteomics -- pulmonary hypertension; Pulmonary circulation -- Periodicals; Pulmonary circulation; Electronic journals -- Sciences; Periodicals; 616.24005
• DOI: 10.1002/pul2.12039
• Languages: English
• ISSNs: 2045-8932

Abstract

Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by sustained elevations of pulmonary artery pressure. To date, we lack circulating, diagnostic, and prognostic markers that correlate to clinical and functional parameters. In this study, we performed mass spectrometry‐based proteomics analysis to identify circulating biomarkers of PAH. Plasma samples from patients with idiopathic pulmonary arterial hypertension (IPAH, N = 9) and matched normal controls ( N = 9) were digested with trypsin and analyzed using data‐dependent acquisition on an Orbitrap mass spectrometer. A total of 826 (false discovery rate [FDR] 0.047) and 461 (FDR 0.087) proteins were identified across all plasma samples obtained from IPAH and control subjects, respectively. Of these, 153 proteins showed >2 folds change ( p < 0.05) between groups. Circulating levels of carbonic anhydrase 2 (CA2), plasma kallikrein (KLKB1), and the insulin‐like growth factor binding proteins (IGFBP1‐7) were quantified by immunoassay in an independent verification cohort ( N = 36 PAH and N = 35 controls). CA2 and KLKB1 were significantly different in PAH versus control but were not associated with any functional or hemodynamic measurements. Whereas, IGFBP1 and 2 were associated with higher pulmonary vascular resistance, IGFBP2, 4, and 7 with decreased 6‐min walk distance (6MWD), and IGFBP1, 2, 4, and 7 with worse survival. This plasma proteomic discovery analysis suggests the IGF axis may serve as important new biomarkers for PAH and play an important role in PAH pathogenesis.